Cocrystal Pharma has received approval from the Australian Human Research Ethics Committee (HREC) to initiate a Phase I trial of CDI-988 for the treatment of Covid-19.
CDI-988 is an oral, broad-spectrum 3CL protease inhibitor designed using Cocrystal’s proprietary drug discovery platform technology.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The double-blind, randomised, dose-escalating, placebo-controlled study aims to to evaluate CDI-988’s tolerability, safety, and pharmacokinetics in healthy volunteers.
Cocrystal president and co-CEO Sam Lee said: “We are excited to have accomplished this milestone and look forward to initiating our CDI-988 clinical programme as an oral treatment for patients with Covid-19, as well as demonstrating our drug discovery platform technology capabilities.”
“CDI-988 was designed to bind to a highly conserved region of coronavirus and other viral proteases.
“Recent findings from our preclinical studies also show pan-viral activity against different RNA viruses, enabling the potential for additional clinical benefits. Further exploration of this pan-viral activity is ongoing.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataCDI-988 demonstrated in vitro potency against SARS-CoV-2 and other coronaviruses. It also had a favourable safety profile and showed pharmacokinetic properties that would support daily oral dosing.
In August last year, Cocrystal Pharma selected hVIVO as a contract research organisation to conduct a Phase IIa human challenge trial of its oral antiviral candidate, CC-42344, for Influenza A.
The double-blind, single-centre, placebo-controlled trial analysed the safety, viral, and clinical measures of oral CC-42344 in participants with influenza A.
